Palvella Therapeutics, Inc. (PVLA) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, and thank you for standing by. Welcome to Palvela's first quarter 2025 financial results and corporate update conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question and answer session. To ask a question during the session, you'll need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised, today's conference is being recorded. I would now like to turn the conference over to your speaker today. Bo Hanwei, please go ahead. Thank you, operator. Good morning and thank you for joining the Palvela Therapeutics Q1 2025 financial results and corporate update call. As a reminder, our press release summarizing today's updates is available under the investor section of our website at www.palvelatx.com. On today's call, we are joined by Wes Coffinan, our chief executive officer, Jeff Martini, our chief scientific officer, and Matt Korenberg, our chief financial officer. Before we begin, please note that today's remarks may include forward-looking statements regarding our development programs, regulatory plans, commercial outlook, and financial performance. These statements are based on current assumptions and subject to risks and uncertainties that may cause actual results to differ. Please refer to our filings with the SEC for more information. And now I'll turn the call over to Wes. Thank you, Bohan. Good morning, everyone. Thank you all for joining us today. This past Monday morning, the Paul Vela team, including our scientific and clinical collaborators, investors, senior advisors, board members, and family members converged on New York City for the ringing of NASDAQ'...